WuXi Biologics is now more undervalued than any other company! In the past two years, the CRO market has been oversupplied, but that's due to the fierce competition in small molecules, while large molecules have always been dominated by WuXi Biologics!

The stock prices of those highly competitive companies are very low, can they still raise funds to expand into large molecules? For example, Pharmaron, Joinn Laboratories, Asymchem, Medicilon, Asymchem, etc. Before the market environment improves, won't WuXi Biologics lead the domestic market for a few more years?

Not to mention the international market, can't the future domestic large molecule drug CRO market accommodate a $50 billion WuXi Biologics? The undervaluation is really excessive! I've already bought WuXi Biologics, won't sell until it doubles, waiting for two years to verify!